首次在 HLA-A*02:01 表达 MAGE-A4 的实体瘤参与者中进行 CDR404 人体研究
第一阶段首次人体研究,旨在评估 CDR404 在表达 MAGE-A4 的实体瘤 HLA-A*02:01 参与者中的安全性、耐受性和抗肿瘤活性
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.
研究概览
详细说明
The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases:
- To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404
- To assess preliminary evidence of anti-tumor activity of CDR404
- To characterise the pharmacokinetics of CDR404
- To characterise the immunogenicity of CDR404
- To assess translational biomarkers
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Dimitrios Chondros Chief Medical Officer, CDR-Life
- 电话号码:+41 44 515 7025
- 邮箱:CDR404-001_Study@CDR-Life.com
学习地点
-
-
-
Copenhagen、丹麦、DK-2100
- 招聘中
- Rigshospitalet
-
首席研究员:
- Iben Spanggaard, MD
-
接触:
- Phase 1 Unit
- 电话号码:+4535457966
- 邮箱:RH-FP-ThePhase1Unit@regionh.dk
-
接触:
- Iben Spanggaard, MD
- 电话号码:+45 35 45 35 45
- 邮箱:iben.spanggaard.01@regionh.dk
-
-
-
-
-
Milan、意大利、20141
- 招聘中
- Isituto Europeo di Oncologia (IEO)
-
接触:
- Giuseppe Curigliano, MD
- 电话号码:+390257489960
- 邮箱:Giuseppe.curigliano@ieo.it
-
首席研究员:
- Guiseppe Curigliano, MD
-
Milan、意大利、20089
- 招聘中
- Istituto Clinico Humanitas
-
首席研究员:
- Matteo Simonelli, MD
-
接触:
- Matteo Simonelli, MD
- 电话号码:+390282244559
- 邮箱:matteo.simonelli@cancercenter.humanitas.it
-
-
-
-
-
Antwerp、比利时、2650
- 招聘中
- Universitair Ziekenhuis Antwerpen
-
首席研究员:
- Hans Prenen, MD
-
接触:
- Amelie Lyssens
- 电话号码:+32 38215580
- 邮箱:studies.oncologie@uza.be
-
Brussels、比利时、1070
- 招聘中
- Institut Jules Bordet
-
首席研究员:
- Nuria Kotecki, MD
-
接触:
- Michele Schroeder
- 电话号码:+3225413833
- 邮箱:michele.schroeder@hubruxelles.be
-
Brussels、比利时、1200
- 招聘中
- Cliniques Universitaires Saint-Luc, UCL Ouvain
-
接触:
- Jean-Pascal Machiels, MD
- 电话号码:+32 27645457
- 邮箱:jean-pascal.machiels@saintluc.uclouvain.be
-
首席研究员:
- Jean-Pascal Machiels, MD
-
Ghent、比利时、9000
- 招聘中
- Universitair Ziekenhuis Gent
-
首席研究员:
- Sylvie Rottey, MD
-
接触:
- Tessa Lefebvre
- 电话号码:+32 38215580
- 邮箱:tessa.lefebvre@uzgent.be
-
-
-
-
Florida
-
Miami、Florida、美国、33136
- 撤销
- University of Miami
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 撤销
- University of Michigan
-
-
Oregon
-
Portland、Oregon、美国、97213
- 招聘中
- Providence Cancer Institute
-
首席研究员:
- Rom Leidner, MD
-
接触:
- Providence Cancer Institute
- 邮箱:CanRsrchStudies@providence.org
-
接触:
- 电话号码:+1-503-215-5763
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19106
- 招聘中
- Pennsylvania Hospital
-
首席研究员:
- Mark Diamond, MD
-
接触:
- Research Team
- 电话号码:+1-215-829-7089
- 邮箱:PAhemoncResearch@uphs.upenn.edu
-
-
-
-
-
Glasgow、英国
- 招聘中
- The Beatson West of Scotland Cancer Center
-
首席研究员:
- Jeff Evans
-
接触:
- Jeff Evans
- 电话号码:(+44)1413017073
- 邮箱:j.evans@crukscotlandinstitute.ac.uk
-
London、英国
- 尚未招聘
- Guys and St Thomas' NHS Foundation Trust
-
首席研究员:
- Rebecca Kristeleit
-
接触:
- Early Phase Research Team
- 电话号码:(+44)20 7188 8103
- 邮箱:gstt.earlyphaseresearchteam@nhs.net
-
-
London
-
Sutton、London、英国、SM2 5PT
- 招聘中
- Royal Marsden Hospital
-
接触:
- Ekta Gosha
- 电话号码:+442089154409
- 邮箱:Ekta.Goshi@icr.ac.uk
-
首席研究员:
- Alec MD Paschalis
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall d'Hebron
-
接触:
- Montserrat Moreno
- 电话号码:98814 +34 932543450
- 邮箱:momoreno@vhio.net
-
首席研究员:
- Alberto Hernando Calvo, MD
-
Barcelona、西班牙、08908
- 招聘中
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
-
接触:
- Carmen Cuadra
- 电话号码:+34 932607294
- 邮箱:ccuadra@iconcologia.net
-
首席研究员:
- Ramon Salazar MD Martin, MD
-
Madrid、西班牙、28041
- 招聘中
- Hospital 12 de Octubre
-
接触:
- Sandra Tapial, Raquel Rodriguez, MariPaz Soriano,
- 电话号码:+34913908922
- 邮箱:unidadfase1.imas12@h12o.es
-
接触:
- Sandra de la Llave, Marta Gutierrez, Elisa Lorente, Lidia Silvo, Veronica Silva
-
首席研究员:
- Guillermo de Velasco, MD
-
Madrid、西班牙、28050
- 招聘中
- START Madrid
-
首席研究员:
- Emiliano Calvo, MD
-
接触:
- Ester Ordonez
- 电话号码:4851 +34 917567800
- 邮箱:ester.ordonez@startmadrid.com
-
接触:
- Sonia Puerta
- 邮箱:sonia.puerta@startmadrid.com
-
Valencia、西班牙、46026
- 招聘中
- Hospital Universitari i Politecnic La Fe
-
接触:
- Lorena, Jimenez
- 电话号码:+34 618734852
- 邮箱:lorena.jimenez@iislafe.es
-
接触:
- Juan Genoves
- 邮箱:juan.genoves@iislafe.es
-
首席研究员:
- Guillermo Suay Montagud, MD
-
Valencia、西班牙、46026
- 招聘中
- Instituto de Investigacion Sanitaria (INCLIVA)
-
接触:
- Maribel Gomez
- 电话号码:+34 961973527
- 邮箱:iblasco@incliva.es
-
接触:
- Inma Blasco
-
首席研究员:
- Desamparados Roda Perez, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Provision of written informed consent
- HLA-A*02:01 positive
- MAGE-A4 positive tumor
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
- Selected advanced solid tumors
- Relapsed from, refractory to, or intolerant of standard therapy
- Measurable disease per RECIST v1.1
- Adequate organ function
- If applicable, must agree to use highly effective contraception
Exclusion Criteria:
- Symptomatic or untreated central nervous system metastasis
- Inadequate washout from prior anticancer therapy
- Significant ongoing toxicity from prior anticancer treatment
- Recent surgery
- Clinically significant cardiac disease
- Active infection requiring systemic antibiotic treatment
- Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes
- Active hepatitis B virus (HBV) or hepatitis C virus (HBC)
- Ongoing treatment with systemic steroids or other immunosuppressive therapies
- Significant secondary malignancy
- History of chronic or recurrent active autoimmune disease requiring treatment
- Uncontrolled intercurrent illness
- Pregnancy or lactation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:CDR404
Dose escalation |
IV infusions |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Presence of dose limiting toxicities (DLTs)
大体时间:From first dose to DLT period (21 days)
|
per Protocol |
From first dose to DLT period (21 days)
|
|
Incidence and severity of (serious) adverse events ([S]AEs)
大体时间:From first dose to 90 days after the last dose
|
AEs, SAEs |
From first dose to 90 days after the last dose
|
|
Anti-tumor response: Overall Response Rate (ORR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease control rate (DCR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Duration of response (DOR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Progression-free Survival (PFS)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Overall Survival (OS)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Maximum serum concentration of CDR404 (Cmax)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Time to maximum serum concentration of CDR404 (Tmax)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Trough serum concentration of CDR404 (Ctrough)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Half-life of CDR404 (t1/2)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Area under the CDR404 serum concentration over time curve (AUC0-T)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
to the end of the dosing interval following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Volume of CDR404 distribution (Vd)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Average serum concentration of CDR404 (Cavg)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Serum drug levels of CDR404 at steady state (CL)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Accumulation ratio of CDR404 (Rac)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Immunogenicity
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Incidence of detectable anti-CDR404 antibodies (ADAs) |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CDR404-001
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.